A copper-binding tripeptide first isolated by Loren Pickart in 1973. INCI-listed as Copper Tripeptide-1 in the cosmetic ingredient register. This review covers the dermal and matrix research literature, mechanism, and regulatory distinction between cosmetic-ingredient and drug status.
THE ORIGIN FRAGMENT: In 1973, biochemist Dr. Loren Pickart made a critical observation: when aged liver tissue was exposed to blood plasma from younger donors, the older cells began expressing younger phenotypes. He isolated the specific factor responsible for this shift—a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) with a massive affinity for binding copper(II) ions. In human tissue, endogenous GHK-Cu concentrations drop by nearly 60% between age 20 and age 60.
PRECLINICAL RESEARCH VECTORS & MECHANISMS The research surrounding GHK-Cu focuses heavily on its role as a master regulator of the extracellular matrix (ECM) and its signaling capabilities in tissue remodeling. The full dossier covers:
ECM Remodeling: Literature detailing the regulation, synthesis, and breakdown of collagen and glycosaminoglycans.
Dermal Fibroblast Activation: Cellular assays showing significant stimulation of structural skin cells and metalloproteinase modulation.
Regulatory Distinction: The legal and structural differences between its INCI cosmetic-ingredient listing and pharmaceutical-drug research status.
PROCUREMENT & COMPLIANCE PROTOCOL Strictly synthesized and supplied for in vitro research, analytical characterization, and laboratory mass spectrometry. Not for human use.
[ Request Full 40-Page Dossier ↗ ] | [ Procure for Research ↗ ]
